EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐World Safety and Efficacy of Biosimilar Trastuzumab Emtansine (T‐DM1) in HER2‐Positive Breast Cancer: A Prospective Single‐Institution Study From India

Divya Gandrala iD, Senthil J Rajappa iD, Krishnamohan Mallavarapu, A Santa iD, B Pavan Kumar iD, Rakesh Pinninti iD, Pallavi S Ladda, Nikhil Pathi iD, Sanath Kandem, Rohan Kamlesh Tewani iD, Vipulkumar Thummar iD, Priya Mehta iD

International Journal of Breast Cancer · 2026-01 · 2026 (1)

DOI: 10.1155/ijbc/8863217 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Breast Cancer, online erschienen am 20.04.2026. Verfasst von Divya Gandrala und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, India, induscancer.com. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Trastuzumab emtansine (T‐DM1) represents an advancement in HER2‐targeted therapy, offering a unique combination of trastuzumab′s specificity and the cytotoxic potency of maytansine. It demonstrates therapeutic efficacy across the spectrum of breast cancer, including both early‐stage and advanced disease. With the emergence of biosimilar formulations, there is a growing need to generate real‐world evidence supporting their clinical performance. This study investigates the effectiveness and safety of a T‐DM1 biosimilar in routine oncology practice across adjuvant and metastatic HER2‐positive breast cancer populations.

Methods

In this prospective, single‐institute study conducted at a tertiary oncology center in India, 116 patients with HER2‐positive breast cancer (51 adjuvant and 65 metastatic) received T‐DM1 biosimilar (Ujvira) between June 2021 and October 2023. Outcomes assessed included overall response rate (ORR), progression‐free survival (PFS), overall survival (OS), and treatment‐emergent adverse events (AEs), graded using CTCAE v5.0.

Results

In the metastatic cohort, ORR was 63.4%, median PFS was 8.0 months (95% CI: 5.8–10.2), and estimated median OS was 18.0 months (95% CI: 16.1–19.9). Clinical benefit rate was 75%. In the adjuvant cohort, 62.7% completed the planned 14 cycles, and treatment was well tolerated. Grade ≥ 3 AEs occurred in 6.9% of all patients, with fatigue and thrombocytopenia being the most common AEs. No unexpected safety signals were observed.

Conclusion

T‐DM1 biosimilar showed outcomes consistent with those reported for the originator in real‐world settings, supporting its broader adoption in both early and advanced HER2‐positive breast cancer. Its affordability may improve access and outcomes in resource‐limited settings.

Schlagwörter

Stichwörter der Autor:innen

HER2-positive breast cancerT-DM1overall survivalprogression-free survivaltargeted therapy

Autor:innen und Institutionen

  • Department of Medical Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, India, induscancer.com.
  • Medical Affairs, Zydus Lifesciences Ltd, Ahmedabad, India.

ORCID-Profile: Divya Gandrala, Senthil J Rajappa, A Santa, B Pavan Kumar, Rakesh Pinninti, Nikhil Pathi, Rohan Kamlesh Tewani, Vipulkumar Thummar, Priya Mehta

Zitieren

APA

Gandrala, D., Rajappa, S. J., Mallavarapu, K., Santa, A., Pavan Kumar, B., Pinninti, R., Ladda, P. S., Pathi, N., Kandem, S., Tewani, R. K., Thummar, V., & Mehta, P. (2026). Real‐World Safety and Efficacy of Biosimilar Trastuzumab Emtansine (T‐DM1) in HER2‐Positive Breast Cancer: A Prospective Single‐Institution Study From India. International Journal of Breast Cancer, 2026(1). https://doi.org/10.1155/ijbc/8863217

Vancouver

Gandrala D, Rajappa SJ, Mallavarapu K, Santa A, Pavan Kumar B, Pinninti R, et al. Real‐World Safety and Efficacy of Biosimilar Trastuzumab Emtansine (T‐DM1) in HER2‐Positive Breast Cancer: A Prospective Single‐Institution Study From India. International Journal of Breast Cancer. 2026;2026(1). doi:10.1155/ijbc/8863217

BibTeX
@article{Gandrala2026,
  author = {Gandrala, Divya and Rajappa, Senthil J and Mallavarapu, Krishnamohan and Santa, A and Pavan Kumar, B and Pinninti, Rakesh and Ladda, Pallavi S and Pathi, Nikhil and Kandem, Sanath and Tewani, Rohan Kamlesh and Thummar, Vipulkumar and Mehta, Priya},
  title = {Real‐World Safety and Efficacy of Biosimilar Trastuzumab Emtansine (T‐DM1) in HER2‐Positive Breast Cancer: A Prospective Single‐Institution Study From India},
  journal = {International Journal of Breast Cancer},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/ijbc/8863217}
}
Kostenlos starten →